Isomerase, a leader in innovative biocatalysis and microbial strain engineering, is pleased to contribute to a newly published iScience paper reporting advances in the development of NV354, a novel therapeutic candidate targeting mitochondrial dysfunction.
The peer‑reviewed study, published in iScience, highlights the potential of NV354 as a next‑generation metabolic therapy designed to support cellular energy production in disorders involving impaired mitochondrial function.
Isomerase’s Contributions
Isomerase was a core scientific contributor to the project. We worked with the Abliva team on their concept of succinate prodrugs to design a molecule that met a challenging target product profile and relied on a deep understanding of cellular metabolism. Isomerase’s contribution includes compound design, bioanalytics, compound profiling, process development, and managing GMP manufacture for preclinical and clinical studies. Some of these efforts are detailed in the manuscript.
“We are proud to see NV354 highlighted in this publication and even more proud of the role our team played in bringing this candidate forward,” said Steven Moss, CTO at Isomerase. “NV354 is an exciting example of how Isomerase can add value to our clients' projects.”
More details can be found here
About Isomerase
Isomerase is an award‑winning and fully integrated synthetic biology partner based at Chesterford Research Park and Solopark near Cambridge, UK. Founded in 2012, we discover and develop next‑generation enzymes, proteins, peptides, and natural products to promote sustainability and human health. Our team draws on decades of experience working with bacteria and fungi, combined with deep capabilities in microbial biology, chemistry, and process innovation, to help our partners progress their products and processes toward commercialization.
For more information, please visit www.isomerase.com or contact